AMLX Company Profile and Key Details

AMLX has shown sold momentum, gaining 33.58% over the past week and 10.7% over the past quarter, though year-to-date performance is up 37.0%. Short-term trend indicators are bearishly aligned (SMA20 6.98%, SMA50 12.3%, SMA200 39.69%). The stock’s 14-day RSI is 59.36 (neutral), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.75% below its high and over 486.92% above its low. Average 10-day trading volume of 925.46 thousand shares is below the 3-month average of 1.08 million, indicating normal recent market interest.

Amylyx Pharmaceuticals, Inc. has 111.19 million shares outstanding. The public float is 83.53 million shares, elevated short interest at 16.89% of float. This equals 14.51 million shares. The short ratio is 12.95 days. Institutional investors hold 112.22% of the float. Insiders own 7.62%. Morningside Venture Investments Ltd holds 7.00 million shares, ALS Invest 1 B.V. has 5.94 million shares and Cohen Joshua B has 3.33 million shares. Over the past six months, insider transactions show net selling. They sold 422.89 thousand shares across 18 transactions.

Amylyx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.33. This means the shares are trading above this model’s fair value.

Amylyx Pharmaceuticals, Inc. generated EPS of -$1.80 over the past year. Five-year average earnings growth is -78.71%. Wall Street analysts project EPS growth of 33.66% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.35. Next year's EPS is expected at $73.41. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $10.00. The high target offers 139.1% upside. The low target suggests -29.68% downside. The mean target is $21.18. This offers 48.95% upside. Amylyx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 8.82%. The prior quarter beat by -3.23%. Over the last six quarters, Apple has recorded several small beats. These include 12.24% in March 04, 2025.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) closed at $14.12 USD, losing -$0.10 (-0.69%) from the previous close of $14.22. The stock is currently mid-range between its 52-week high and low $4.71 and $18.61. With a market capitalization of about $1.17 billion, Amylyx Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.10). Key stats such as the average daily volume over the past year has been around 1.10 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua Cohen, the company employs approximately 123 people and listed since January 07, 2022. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Amylyx Pharmaceuticals, Inc. trades at a P/E ratio of -10.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.73 trading at moderately above to book value. The P/FCF stands at -9.76, also above market averages.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) shares are up 37.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Amylyx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -10.43. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $26.76, suggesting 88.19% upside. Our AI forecast model points to short-term weakness (-13.36% over two weeks), a medium-term rise (3.23% over three months), and a longer-term gain (204.5% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Amylyx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.36%, with price expected at $12.32 by June 11, 2026, within a range of $11.59 to $13.09 3-Month Outlook: Projected rise of 3.23%, reaching $14.68 by August 26, 2026, with a range of $14.46 to $14.92. 1-Year Outlook: Projected gain of 204.5%, with price at $43.30 by May 28, 2027, within a range of $39.92 to $57.03.